ASX - By Stock
|
BNL |
Re:
Ann: Significant Helium Discovery at State 16 Well
|
|
Bpharma
|
191 |
63K |
8 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
191
|
63K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: US Department of Defense Grants US $2m for R327G
|
|
Bpharma
|
10 |
6.0K |
10 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
10
|
6.0K
|
10
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Significant Helium Discovery at State 16 Well
|
|
Bpharma
|
191 |
63K |
2 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
191
|
63K
|
2
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Significant Helium Discovery at State 16 Well
|
|
Bpharma
|
191 |
63K |
3 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
191
|
63K
|
3
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Significant Helium Discovery at State 16 Well
|
|
Bpharma
|
191 |
63K |
2 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
191
|
63K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B
|
|
Bpharma
|
22 |
9.6K |
1 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
22
|
9.6K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B
|
|
Bpharma
|
22 |
9.6K |
5 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
22
|
9.6K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
|
|
Bpharma
|
72 |
20K |
2 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
72
|
20K
|
2
|
|
ASX - By Stock
|
CND |
Re:
CND chart
|
|
Bpharma
|
45 |
14K |
2 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
45
|
14K
|
2
|
|
ASX - By Stock
|
PVE |
Re:
Ann: PVE - Podere Maiar-1 Slick Line Operations Results
|
|
Bpharma
|
3 |
1.9K |
2 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
3
|
1.9K
|
2
|
|
ASX - By Stock
|
LMG |
Re:
Ann: LMG Entitlement Offer closing date extended
|
|
Bpharma
|
6 |
4.7K |
3 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
6
|
4.7K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
|
|
Bpharma
|
72 |
20K |
5 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
72
|
20K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
|
|
Bpharma
|
72 |
20K |
3 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
72
|
20K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
|
|
Bpharma
|
72 |
20K |
7 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
72
|
20K
|
7
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Significant Helium Discovery at State 16 Well
|
|
Bpharma
|
191 |
63K |
3 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
191
|
63K
|
3
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Significant Helium Discovery at State 16 Well
|
|
Bpharma
|
191 |
63K |
4 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
191
|
63K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Ethics Approval Broadens to All Topical Infections
|
|
Bpharma
|
17 |
4.8K |
9 |
24/06/24 |
24/06/24 |
ASX - By Stock
|
17
|
4.8K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: R327 added to WHO List of Antibacterial Products
|
|
Bpharma
|
25 |
8.5K |
7 |
22/06/24 |
22/06/24 |
ASX - By Stock
|
25
|
8.5K
|
7
|
|
ASX - By Stock
|
EUR |
Re:
Initial investors returning to the roost
|
|
Bpharma
|
126 |
40K |
0 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
126
|
40K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: R327 added to WHO List of Antibacterial Products
|
|
Bpharma
|
25 |
8.5K |
6 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
25
|
8.5K
|
6
|
|
ASX - By Stock
|
LMG |
Re:
general discussion
|
|
Bpharma
|
2.3K |
1.0M |
5 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
2.3K
|
1.0M
|
5
|
|
ASX - By Stock
|
RCE |
Re:
[WEBINAR REPLAY] What it takes to get a new drug to market in Australia
|
|
Bpharma
|
32 |
11K |
1 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
32
|
11K
|
1
|
|
ASX - By Stock
|
LMG |
Re:
Ann: LMG Equity Raising Presentation
|
|
Bpharma
|
39 |
23K |
0 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
39
|
23K
|
0
|
|
ASX - By Stock
|
JGH |
Re:
Ann: Jade to Fast Track Path to Gas Production
|
|
Bpharma
|
5 |
4.1K |
1 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
5
|
4.1K
|
1
|
|
ASX - By Stock
|
5EA |
Re:
5E Advanced Materials Provides Organizational Update
|
|
Bpharma
|
11 |
3.8K |
3 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
11
|
3.8K
|
3
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Significant Helium Discovery at State 16 Well
|
|
Bpharma
|
191 |
63K |
2 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
191
|
63K
|
2
|
|
ASX - By Stock
|
CND |
Re:
CND chart
|
|
Bpharma
|
45 |
14K |
0 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
45
|
14K
|
0
|
|
ASX - By Stock
|
CND |
Re:
CND chart
|
|
Bpharma
|
45 |
14K |
0 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
45
|
14K
|
0
|
|
ASX - By Stock
|
CND |
Re:
CND chart
|
|
Bpharma
|
45 |
14K |
3 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
45
|
14K
|
3
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Significant Helium Discovery at State 16 Well
|
|
Bpharma
|
191 |
63K |
5 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
191
|
63K
|
5
|
|
ASX - By Stock
|
CND |
Re:
Woooooo Hoooooo Go CND :)$$$$$
|
|
Bpharma
|
48 |
21K |
2 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
48
|
21K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
[WEBINAR REPLAY] What it takes to get a new drug to market in Australia
|
|
Bpharma
|
32 |
11K |
1 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
32
|
11K
|
1
|
|
ASX - By Stock
|
LMG |
Re:
Ann: Trading Halt
|
|
Bpharma
|
27 |
12K |
0 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
27
|
12K
|
0
|
|
ASX - By Stock
|
BNL |
Re:
Ann: State 16 Well Drilled to TD with Logs Confirming Gas
|
|
Bpharma
|
44 |
13K |
2 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
44
|
13K
|
2
|
|
ASX - By Stock
|
BNL |
Re:
Ann: State 16 Well Drilled to TD with Logs Confirming Gas
|
|
Bpharma
|
44 |
13K |
3 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
44
|
13K
|
3
|
|
ASX - By Stock
|
BNL |
Re:
Ann: State 16 Intermediate Hole Section Drilled
|
|
Bpharma
|
53 |
15K |
4 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
53
|
15K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Approval to Start Phase I/II Diabetic Foot Ulcer Study
|
|
Bpharma
|
30 |
13K |
1 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
30
|
13K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Approval to Start Phase I/II Diabetic Foot Ulcer Study
|
|
Bpharma
|
30 |
13K |
1 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
30
|
13K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Approval to Start Phase I/II Diabetic Foot Ulcer Study
|
|
Bpharma
|
30 |
13K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
30
|
13K
|
5
|
|
ASX - By Stock
|
CND |
Re:
Woooooo Hoooooo Go CND :)$$$$$
|
|
Bpharma
|
48 |
21K |
4 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
48
|
21K
|
4
|
|
ASX - By Stock
|
CND |
Re:
Woooooo Hoooooo Go CND :)$$$$$
|
|
Bpharma
|
48 |
21K |
2 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
48
|
21K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
51 |
21K |
3 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
51
|
21K
|
3
|
|
ASX - By Stock
|
LMG |
Re:
Ann: Magnesium Oxide Production
|
|
Bpharma
|
47 |
20K |
1 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
47
|
20K
|
1
|
|
ASX - By Stock
|
PVE |
Re:
Ann: Change of Director's Interest Notice
|
|
Bpharma
|
7 |
2.1K |
1 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
7
|
2.1K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: MCRI Pilot Study- Positive Efficacy Data for Lung Infections
|
|
Bpharma
|
19 |
6.1K |
1 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
19
|
6.1K
|
1
|
|
ASX - By Stock
|
CND |
Re:
CND chart
|
|
Bpharma
|
45 |
14K |
1 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
45
|
14K
|
1
|
|
ASX - By Stock
|
CND |
Re:
Woooooo Hoooooo Go CND :)$$$$$
|
|
Bpharma
|
48 |
21K |
1 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
48
|
21K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: MCRI Pilot Study- Positive Efficacy Data for Lung Infections
|
|
Bpharma
|
19 |
6.1K |
2 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
19
|
6.1K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
51 |
21K |
0 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
51
|
21K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: MCRI Pilot Study- Positive Efficacy Data for Lung Infections
|
|
Bpharma
|
19 |
6.1K |
6 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
19
|
6.1K
|
6
|
|